--- title: "08:45 ET\n\t\t\t\n\t\t\t\n\t\t\t\tPepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG" description: "Levi & Korsinsky, LLP has announced a class action securities lawsuit against PepGen Inc. (NASDAQ: PEPG) for alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025. The " type: "news" locale: "en" url: "https://longbridge.com/en/news/252242431.md" published_at: "2025-08-08T12:52:18.000Z" --- # 08:45 ET PepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG > Levi & Korsinsky, LLP has announced a class action securities lawsuit against PepGen Inc. (NASDAQ: PEPG) for alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025. The lawsuit claims that the company misrepresented the effectiveness and safety of its lead product candidate, PGN-EDO51, and that the CONNECT2 study was deficient for FDA approval. Investors have until August 8, 2025, to request lead plaintiff status, with no costs to participate in the lawsuit. , /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in **PepGen Inc.** ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. **CLASS DEFINITION:** The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=160189&wire=4 **PEPG** investors may also contact Joseph E. Levi, Esq. via email at \[email protected\] or by telephone at (212) 363-7500. **CASE DETAILS:** The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times. **WHAT'S NEXT?** If you suffered a loss in PepGen Inc. during the relevant time frame, you have until **August 8, 2025** to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. **NO COST TO YOU:** If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. **There is no cost or obligation to participate.** **WHY LEVI & KORSINSKY:** Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. **CONTACT:** Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 \[email protected\] Tel: (212) 363-7500 Fax: (212) 363-7171 www.zlk.com SOURCE Levi & Korsinsky, LLP ### Related Stocks - [PEPG.US - PepGen](https://longbridge.com/en/quote/PEPG.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Vera Therapeutics Names Matt Skelton Chief Commercial Officer | Vera Therapeutics Inc. has appointed Matt Skelton as Chief Commercial Officer, effective immediately. Skelton has extens | [Link](https://longbridge.com/en/news/273989666.md) | | PepGen Names Joseph Vittiglio Chief Business and Legal Officer | PepGen Inc. has appointed Joseph Vittiglio as Chief Business and Legal Officer. Vittiglio has over 20 years of experienc | [Link](https://longbridge.com/en/news/268944552.md) | | PepGen Inc. Granted U.S. Patent for Proprietary PGN-EDODM1 Molecule, Extending Exclusivity Into 2042 | PepGen Inc. has been granted a new U.S. patent for its PGN-EDODM1 molecule, developed through its Enhanced Delivery Olig | [Link](https://longbridge.com/en/news/265517593.md) | | PepGen reports third quarter net loss of $18.0 million | PepGen Inc. reported a third-quarter net loss of $18.0 million, or $(0.52) per share, for the period ending September 30 | [Link](https://longbridge.com/en/news/265515776.md) | | Major Stakeholder Makes Bold Move with PepGen Inc. Stock Purchase! | Oxford Sciences Innovation plc has purchased 200,000 shares of PepGen Inc. stock for $640,000. PepGen's recent updates h | [Link](https://longbridge.com/en/news/259727198.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.